Radiology
Hospitals have the opportunity to speed up diagnosis through advances in AI. In addition to these awards, Mary-Brenda
was recently recognised by Innovate UK in its prestigious ‘Women In Innovation’ 2026 line-up, and was individually spotlighted by UK Research and Innovation (UKRI) among women founders shaping the UK’s future industries. Emily Nott, Head of Inclusive Innovation, at
Innovate UK, said: “Whether an award winner or highly commended applicant, each member of this cohort is working towards delivering significant economic and social impact for the nation through innovation.”
The future of AI development The technology is now building on this promising foundation, but what does the future hold for AI technology, and what hurdles need to be overcome? Mary-Brenda points out that AI is progressing incredibly quickly, but the translation of good AI into healthcare isn’t moving quickly enough: “We are seeing extraordinary advances in research, but there is still a huge gap between demonstrating the technology on paper and getting it safely into the hands of clinicians and patients. It is right that the standard of evidence and safety should be high, when developing technology that could influence diagnosis or treatment – but, at the same time, there are unnecessary barriers,” she commented. Startups can spend years navigating
fragmented procurement and regulatory systems, she warned: “The danger isn’t only adopting unsafe AI too quickly. We also need to consider the cost of adopting genuinely beneficial technology too slowly, leaving patients to continue to experience problems that technology could solve,” she asserted. Mary-Brenda believes the UK is a great place
to build healthcare technology: “We have world- leading universities, the NHS, excellent clinicians and researchers, and organisations like Innovate UK supporting innovation. The biggest
opportunity is connecting those pieces much more effectively. For an early-stage MedTech company, the hardest part isn’t inventing the technology; it is crossing the gap between promising research to a solution that is clinically validated, regulated, procured and deployed. She suggests that the Government could make a huge difference by creating clearer, faster pathways for promising companies to access clinical validation environments, NHS data, regulatory guidance and early procurement. Funding matters too, however. “Medical AI companies have to generate substantial clinical and regulatory evidence before they can meaningfully commercialise – that creates a funding gap between academic research grants and conventional venture capital,” she points out. According to Mary- Brenda, the NHS could become a place where companies validate innovation and one of the “world’s best early adopters of innovation that has been demonstrated to work.” “We have an opportunity to build globally important healthcare companies, here in the UK, and improve NHS healthcare at the same time,” she exclaimed. “A hospital shouldn’t have to buy the newest multi-million-pound scanner to benefit from advances in AI. If we can deploy this technology across existing infrastructure, and across mixed fleets, there is the potential to make advanced imaging more accessible, not just in the NHS and in international healthcare systems, but also in lower resource healthcare systems as well. This is a solution to a global problem,” she continued. “Ultimately, success for me isn’t simply getting
the AI product approved or just building a valuable company. I founded GenScan AI because I know what it means when diagnosis comes too late. So, in the next five years, success for me is millions of patients getting diagnosed sooner because of something we built and I want that
30
www.clinicalservicesjournal.com I November 2026
impact to reach billions. I want us to reach the point where patients around the world are getting faster answers and care, while there is still time to make a difference. That is my vision,” she concluded.
References 1.
https://www.rcr.ac.uk/news-policy/ latest-updates/alarm-bells-should-be- ringing-staff-shortages-causing-extremely- dangerous-delays-to-diagnosis-and-cancer- care-doctors-warn/
2.
https://www.rcr.ac.uk/news-policy/latest- updates/nearly-half-of-nhs-trusts-missing- test-waiting-time-target-as-backlogs-grow/
3. ‘Alarm bells should be ringing’: staff shortages causing ‘extremely dangerous’ delays to diagnosis and cancer care, doctors warn, RCR.
4. Radiology negligence costs NHS £230 million, Healthcare Today, 30 Jan, 2026. Accessed at:
https://healthcaretoday.com/article/ radiology-negligence-costs-nhs-230-million
5. Accessed at:
https://bmjgroup.com/every- month-delayed-in-cancer-treatment-can- raise-risk-of-death-by-around-10/
Further reading 6.
https://proceedings.mlr.press/v315/akoda26a. html
7.
https://www.ukri.org/news/innovate-uk- backs-100-women-shaping-the-uks-future- industries/
8.
https://www.entrepreneurscompany.org/ news/easi26-final
9.
https://guardian.ng/news/akoda- wins-nigeria-prize-for-science-innovation- receives-100000/
10.
https://www.founderland.org/press/ forwardgrantq42025winner
11.
https://nationalaccordnewspaper.com/fg- moves-to-fast-track-mary-brenda-akodas-ai- mri-breakthrough-into-nigerian-hospitals/
CSJ
luuuusa -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71